Loading...

Home
ETF
ALLO

ALLO

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

ALLO News

Allogene Therapeutics Q1 2026 Earnings Call Insights

May 14 2026seekingalpha

Allogene Therapeutics Q1 Earnings Beat Expectations

May 13 2026seekingalpha

Allogene Therapeutics Announces $175 Million Stock Offering

May 12 2026seekingalpha

Allogene Showcases CAR T Therapy Potential at AACR Meeting

Apr 20 2026Newsfilter

Allogene Publishes Preclinical Data for ALLO-329 in Autoimmune Diseases

Apr 15 2026Newsfilter

Allogene Therapeutics Prices $175M Public Offering of Common Stock

Apr 15 2026seekingalpha

Allogene Therapeutics Prices $175 Million Public Offering

Apr 15 2026NASDAQ.COM

Allogene Therapeutics Prices Public Offering at $2.00 per Share

Apr 15 2026Yahoo Finance

Amazon Nears Globalstar Acquisition, Stock Soars

Apr 14 2026seekingalpha

Allogene Therapeutics Proposes $175 Million Public Offering

Apr 14 2026NASDAQ.COM

Allogene Therapeutics Plans $175M Public Offering of Common Stock

Apr 13 2026seekingalpha

Stock Price Movements of Various Companies

Apr 13 2026CNBC

Allogene Therapeutics CAR-T Therapy Shows Promising Phase 2 Trial Results

Apr 13 2026seekingalpha

Allogene's Cancer Treatment Trial Data Shows Significant Improvement

Apr 13 2026stocktwits

Cema-Cel Treatment Shows Significant Efficacy in LBCL Trial

Apr 13 2026Newsfilter

Analysts Predict 180% Upside for Allogene Therapeutics

Apr 12 2026Yahoo Finance